Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy

Figure 2

Recurrence-free survival (RFS) of stage II-III colorectal cancer patients according to treatment. (A) Kaplan-Meier curves for the RFS of patients with the CpG island methylation phenotype (CIMP)-low/negative CRCs. The three-year RFS for patients treated by surgery with adjuvant chemotherapy and those treated by surgery alone was 82.4% and 86.5%, respectively. (B) Kaplan-Meier curves for the RFS of patients with CIMP-high CRCs. The three-year RFS for the surgery with adjuvant chemotherapy group and the surgery alone group was 100% and 71.4%, respectively.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us